Gut Microbiome & Treatment for Gynecological Cancer Patients Receiving

Status Recruiting

Clinical Trial Summary

30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.

Clinical Trial Description

30 patients diagnosed with advanced or recurrent gynecological cancer who plan to receive immunotherapy treatment with a checkpoint inhibitor at AHMG AdventHealth Orlando Gynecological Oncology Group are recruited. Patients will be recruited 1-2 weeks prior to the beginning of treatment and appropriate informed consent will be obtained. Fecal samples; blood; saliva and vaginal swab samples will be collected among participants prior to their first treatment, after four doses of immunotherapy, and again at the completion of immunotherapy (follow-up). These 4 biomarker samples will undergo metatranscriptomic analysis, also known as RNAseq, method of sample analysis. Only RNA molecules are sequenced, while DNA is degraded. for bacterial community analysis. These findings will help to design a future study to examine the role of the gut microbiome in antitumor immunity and its effect on immune checkpoint inhibitor therapy for advanced or recurrent gynecological cancer. NHANES Food Frequency Questionnaire will be collected prior to participants' first treatments. The short-term goals of this pilot study are to obtain preliminary data on the gut bacterial microbiome of patients with advanced or recurrent gynecological cancer. The long-term goals of this study is to begin to understand how the gut microbiome changes within an individual patient undergoing immunotherapy, to gut microbiome differs among patients undergoing immunotherapy, and to examine whether the gut microbiome is associated with the response to cancer immunotherapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04957511
Study type	Observational
Source	Viome
Contact	Momchilo Vuyisich, PhD
Phone	855 958 4663
Email	studies@viome.com
Status	Recruiting
Phase
Start date	June 29, 2021
Completion date	June 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04890327` - Web-based Family History Tool	N/A
Not yet recruiting	`NCT05467319` - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS	Phase 3
Recruiting	`NCT05478876` - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract	N/A
Active, not recruiting	`NCT04899492` - Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery	N/A
Terminated	`NCT03658109` - Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone	Early Phase 1
Recruiting	`NCT05296512` - Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer	Phase 2
Not yet recruiting	`NCT06398314` - Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors	N/A
Completed	`NCT01679483` - Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer	N/A
Completed	`NCT01444924` - Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery	Phase 2
Recruiting	`NCT05053230` - A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer	N/A
Recruiting	`NCT04534075` - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial	Phase 3
Active, not recruiting	`NCT04584957` - Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.)	N/A
Completed	`NCT03292328` - Yoga for Symptoms of Nerve Damage Caused by Chemotherapy	N/A
Completed	`NCT02459301` - A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies	Phase 1
Completed	`NCT05131490` - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients	N/A
Active, not recruiting	`NCT03899376` - A Trial Comparing Acute Toxicity in Patients With Gynecological Cancer Treated With VMAT	N/A
Not yet recruiting	`NCT05407987` - Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)	Phase 3
Recruiting	`NCT05891470` - To Explore the Benefits of the MonaLisa Touch® System in Gynaecological Cancer Patients Treated by (Chemo)-RT	N/A
Not yet recruiting	`NCT05974995` - Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer	N/A
Withdrawn	`NCT04368130` - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms